Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tudorza

- PMLiVE

Almirall eyes $62m takeover of multicytokine specialist Bioniz

Gains clinical-stage drug for cutaneous T-cell lymphoma

AstraZeneca AZ

AZ builds case for its COPD triple as it chases GSK’s Trelegy

Awaiting approvals in Europe and the US

- PMLiVE

McCann’s Breath of Life diagnostic wins Cannes Lion prize

Grand Prix awarded for first time in three years

- PMLiVE

Novartis first to benefit from NICE advice on ‘patient preference’

Consultancy spin-off looking to expand services

- PMLiVE

AZ prepares to file COPD triple, taking on rival GSK

Latest salvo in combination trials competition

- PMLiVE

FDA rejects GSK’s Nucala for COPD

Says evidence that Nucala was effective in preventing COPD exacerbations was insufficient

AstraZeneca AZ

AZ rival to GSK’s COPD drug Anoro fails head-to-head test

Its combo missed two of the main endpoints of the study

- PMLiVE

Almirall acquires Allergan’s dermatology portfolio for $650m

The pharma group buys four products along with Allergan's first-in-class antibiotic Seysara

- PMLiVE

AZ’s Fasenra hit by COPD trial failure

Results give advantage to respiratory rivals GSK

- PMLiVE

GSK gets maintenance indication for Trelegy

Will now treat airflow obstruction in COPD patients

- PMLiVE

FDA hands GSK a reprieve by blocking Novartis generic

The Advair rival could be delayed until 2019

AstraZeneca AZ

AZ’s COPD triple data sets up market clash with GSK

KRONOS trial showed significant improvements in lung function tests over two-drug combos

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links